Y-mAbs enters into Worldwide Exclusive License Agreement for SADA Technology – a Novel Radioimmunotherapy Platform 15 April 2020
Y-mAbs Therapeutics, Inc. a late-stage clinical biopharmaceutical company focused on the development... Read more
Y-mAbs Therapeutics, Inc. a late-stage clinical biopharmaceutical company focused on the development... Read more
Servier, an independent international pharmaceutical company, announced today that it has entered into... Read more
On April 01, 2020, Y-mAbs announced that the Company has completed the submission of its Biologics License... Read more
NORGINE B.V. ACQUIRES AZANTA A/S STRENGTHENING ITS POSITION AS A LEADING EUROPEAN SPECIALIST PHARMACEUTICAL... Read more
During the corona crisis, DANSK BIOTEK is of course following the advice provided by the Danish Government... Read more
In 2019, Accelerace celebrated its 10th anniversary. However, Accelerace was never supposed to become... Read more
NEW YORK, Dec. 12, 2019 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”)... Read more
COPENHAGEN, Denmark, November 21, 2019 / B3C newswire / — MC2 Therapeutics, an emerging pharmaceutical... Read more
NEW YORK, Nov. 01, 2019 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”)... Read more